Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Minghui’s MHB088C will soon start phase 3 in China.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
